Abstracts

Citation

Geri Donenberg, Kathleen George, Nicole Montañez, Emma Davies Smith, Emile Brouwers, Patricia Mandima, Tarisai Bere, Suzen Maonera, Gaerolwe Masheto, Daphne Gadama, Tisungane Mvalo, Lisa Gavin, Wezi Mwenda, Ellen Townley, Dorothy Dow. Implementation Outcomes of IMPAACT 2016: A Peer-Led Mental Health Intervention for Youth with HIV. Presented at: CROI 2026; 2026 Feb 25.

Citation

Jillian Pintye, Hideaki Okochi, Tariro Chawana, Esaú João, Sherika Hanley, Linda Aurpibul, Chelsea Stotz, Katie McCarthy, Patrick Jean-Philippe, Nahida Chakhtoura, Sean Brummel, Jeremiah Momper, Lameck Chinula, Shahin Lockman, Monica Gandhi. In Utero Exposure of Dolutegravir and Efavirenz Assessed via Hair Levels in IMPAACT 2010 Trial. Presented at: CROI 2026; 2026 Feb 24.

Citation

Aditya Gaur, Kristin Baltrusaitis, Edmund Capparelli, Elizabeth Lowenthal, Mark Marzinke, Herta Crauwels, Amy Cheung, Ellen Townley, John Moye, Michael Whitton, Gaerolwe Masheto, Sisinyana Ruth Mathiba, Barbara Heckman, Carolyn Bolton Moore, IMPAACT 2017 Team. Long-Acting Cabotegravir+Rilpivirine in Adolescents: IMPAACT 2017 Week 96 & End of Study Results. Presented at: CROI 2026; 2026 Feb 24.

Citation

Isabelle Roseto, Lori Silveria, Kaili Curtis, Jennifer Canniff, Adriana Weinberg, Christiana Smith. Characterizing Immune Activation in HIV-Exposed but Uninfected Infants in the First Year of Life. Presented at: CROI 2026.

Citation

Mo Archary, Jorge Pinto, Edmund Caparelli, Ed Acosta, Amy Cheung, Herta Crauwels, Ellen Townley, Jack Moye, Mark Giganti, Rachel Scheckter, Barb Heckman, Cristina Hofer, Mrinmayee Dhar, Sisinyana Ruth Mathiba, CRAYON/IMPAACT 2036 Study Team. Safety and pharmacokinetics of long-acting cabotegravir and rilpivirine in young children 10 to 40 kg. Presented at: CROI 2026; 2026 Feb 24.

Citation

Jia Chen Gan, Elizabeth J. McFarland, Camlin Tierney, Alka Khaitan, Deborah Persaud, Mark Cotton, Dwight Yin, Jack Moye, Hans Spiegel, Macpherson Mallewa, Anne Coletti, Charlotte Perlowski, Tisungane Mvalo, Diane Costello, Chelsea Stotz, Edmund Capparelli, IMPAACT 2008 Study Team. Higher HIV viremia was associated with accelerated VRC01 clearance in infants receiving early ART, leading to lower antibody exposure and highlighting the need for optimal bNAb dosing strategies. Presented at: CROI 2026; 2026 Feb 23.

Citation

Elizabeth J. McFarland, Edmund V. Capparelli, Mark J. Giganti, Kelly Seaton, Caroline Brackett, Charlotte Perlowski, Dwight E. Yin, Hans Spiegel, Jack Moye, Sai Majji, Paul A. Harding, Richard A. Koup, Georgia Tomaras, Coleen K. Cunningham, IMPAACT P1112 team. Broadly Neutralizing Antibodies in Oral Secretions After Administration to Newborns Exposed to HIV. Presented at: CROI 2026; 2026 Feb 25.

Citation

Elizabeth J. McFarland, Edmund V. Capparelli, Madeline Abbott, Camlin Tierney, Charlotte Perlowski, Mutsawashe Bwakura-Dangarembizi, Tsungai Mhembere, Hazzie Mvula, Patrick Jean-Philippe, Jack Moye, Diane Costello, Sarah Wojcinski, Bob C. Lin, Ellen Chadwick, IMPAACT P1115 Team. Neutralizing antibody, VRC01, PK and safety among infants initiating very early ART in IMPAACT P1115. Presented at: CROI 2026; 2026 Feb 23.

Citation

Soumia Bekka, Adit Dhummakupt, Sijy O’Dell, Emily Tourtellott, Bryan S. Nelson, Kimesh L. Naidoo, Bernadette Malunda, Mutsa Bwakura-Dangarembizi, Diane Costello, Dwight E. Yin, Sai Majji, Reda Rawi, Ellen G. Chadwick, Nicole Doria-Rose, Deborah Persaud. Harnessing Proviruses to Define bNAb Sensitivity in Infants With In-Utero HIV-1 (IMPAACT P1115). Presented at: CROI 2026.

Citation

Patience Atuhaire, Mark Giganti, Flynn McMorrow, Maxensia Owor, Philippa Musoke, Mary Glenn Fowler, PROMISE 1077BF team. TORCH Infections as Risk Factor For Adverse Birth Outcomes Among HIV-Exposed Neonates in Uganda. Presented at: CROI 2026; 2026 Feb 23.